Ida B. Kristensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ida B. Kristensen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Henrik J. Ditzel
University of Southern Denmark
2 shared publications Jacob H. Christensen
Department of Haematology Odense University Hospital Odense Denmark
2 shared publications- Lars Melholt Rasmussen
Department of Clinical Biochemistry and Pharmacology (L.M.R.), Odense University Hospital, Denmark
2 shared publications - Lise Pedersen
Department of Clinical Biochemistry Holbæk Hospital Holbæk Denmark
2 shared publications Maria B. Lyng
Institute of Molecular Medicine University of Southern Denmark Odense Denmark
2 shared publicationsNiels Abildgaard
Institute of Clinical Research University of Southern Denmark Odense Denmark
2 shared publications
Latest Publications
- 23 April 2013
- Published by Wiley in European Journal of Haematology
- Vol. 91 (3) , 196-200
Decorin is down‐regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF‐induced myeloma plasma cell viability and migration
Objectives: Decorin is a stromal‐produced small leucine‐rich proteoglycan known to attenuate tumour pro‐survival, migration, proliferation and angiogenic signalling pathways. Recent studies have shown that decorin interacts with the hepatocyte growth factor (HGF) receptor c‐Met, a potential key pathway in multiple myeloma (MM).Methods: Decorin levels in paired peripheral blood and bone marrow plasma samples from healthy volunteers (HV) (n = 23), and patients with monoclonal gammopathy of undetermined significance (MGUS) (n = 41) and MM (n = 19) were determined by ELISA. Further, the ability of decorin to inhibit HGF‐induced effects on MM cell lines were analysed in vitro using cell viability and Transwell migration assays.Results: We found that decorin concentrations were significantly higher (P < 0.05) in bone marrow (BM) plasma from HVs (median 35.2 ng/mL; range, 15.3–99.1) compared with MGUS (median 22.5 ng/mL; range, 11.1–59.5) and patients with MM (median 21.5 ng/mL; range, 10.6–35.9). Decorin levels were higher in BM plasma than in peripheral blood in all groups, with a BM/PB ratio of 3.9, 3.4 and 2.5 for HV, MGUS and MM, respectively. A positive correlation (Spearman's ρ = 0.51, P < 0.05) was found between simultaneously measured levels of HGF and decorin in BM plasma in HVs, but not in MGUS or MM samples. Functionally, decorin inhibited HGF‐induced migration and viability of INA‐6 and ANBL‐6 MM cell lines, independent of c‐Met down‐regulation.Conclusion: Our results show that decorin is down‐regulated in MGUS and MM bone marrow plasma and that it inhibits HGF‐induced viability and migration of myeloma cell lines in vitro.
- 23 April 2013
- Published by Wiley in European Journal of Haematology
- Vol. 91 (3) , 196-200
Decorin is down‐regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF‐induced myeloma plasma cell viability and migration
Objectives: Decorin is a stromal‐produced small leucine‐rich proteoglycan known to attenuate tumour pro‐survival, migration, proliferation and angiogenic signalling pathways. Recent studies have shown that decorin interacts with the hepatocyte growth factor (HGF) receptor c‐Met, a potential key pathway in multiple myeloma (MM).Methods: Decorin levels in paired peripheral blood and bone marrow plasma samples from healthy volunteers (HV) (n = 23), and patients with monoclonal gammopathy of undetermined significance (MGUS) (n = 41) and MM (n = 19) were determined by ELISA. Further, the ability of decorin to inhibit HGF‐induced effects on MM cell lines were analysed in vitro using cell viability and Transwell migration assays.Results: We found that decorin concentrations were significantly higher (P < 0.05) in bone marrow (BM) plasma from HVs (median 35.2 ng/mL; range, 15.3–99.1) compared with MGUS (median 22.5 ng/mL; range, 11.1–59.5) and patients with MM (median 21.5 ng/mL; range, 10.6–35.9). Decorin levels were higher in BM plasma than in peripheral blood in all groups, with a BM/PB ratio of 3.9, 3.4 and 2.5 for HV, MGUS and MM, respectively. A positive correlation (Spearman's ρ = 0.51, P < 0.05) was found between simultaneously measured levels of HGF and decorin in BM plasma in HVs, but not in MGUS or MM samples. Functionally, decorin inhibited HGF‐induced migration and viability of INA‐6 and ANBL‐6 MM cell lines, independent of c‐Met down‐regulation.Conclusion: Our results show that decorin is down‐regulated in MGUS and MM bone marrow plasma and that it inhibits HGF‐induced viability and migration of myeloma cell lines in vitro.
- Open Access
- 22 February 2013
- Published by Wiley in British Journal of Haematology
- Vol. 161 (3) , 373-382
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease
Summary: Lytic bone disease (LBD) in multiple myeloma (MM) is caused by osteoclast hyperactivation and osteoblast inhibition. Based on in vitro studies, the hepatocyte growth factor (HGF) pathway is thought to be central in osteoblast inhibition. We evaluated the gene expression of the HGF pathway in vivo using bone marrow biopsies (BMBs) of patients with MM and monoclonal gammopathy of undetermined significance (MGUS), and healthy volunteers (HV). BMBs (N = 110) obtained at diagnosis were snap‐frozen and used to evaluate gene expression by quantitative reverse transcription polymerase chain reaction. LBD was evaluated using standard radiographs. Enzyme‐linked immunosorbent assay (ELISA) was performed on matched bone marrow plasma and immunohistochemistry on matched formalin‐fixed paraffin‐embedded biopsies. Gene expression of HGF, SDC1, and MET in BMBs were significantly altered in MM versus HV and MGUS, and HGF and MET correlated with the extent of LBD. A significant correlation between gene and protein expression levels was observed for SDC1 (Syndecan‐1) and HGF. The HGF bone marrow plasma level was significantly lower in MM patients with no/limited versus advanced LBD. Our novel approach using snap‐frozen BMBs seems generally applicable because it allows evaluation of gene expression independent of the extent of MM plasma‐cell infiltration. Our study highlights the importance of the HGF pathway in MM LBD.
- 22 February 2013
- Published by Wiley in British Journal of Haematology
- Vol. 161 (3) , 373-382
Open AccessHepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease
Summary: Lytic bone disease (LBD) in multiple myeloma (MM) is caused by osteoclast hyperactivation and osteoblast inhibition. Based on in vitro studies, the hepatocyte growth factor (HGF) pathway is thought to be central in osteoblast inhibition. We evaluated the gene expression of the HGF pathway in vivo using bone marrow biopsies (BMBs) of patients with MM and monoclonal gammopathy of undetermined significance (MGUS), and healthy volunteers (HV). BMBs (N = 110) obtained at diagnosis were snap‐frozen and used to evaluate gene expression by quantitative reverse transcription polymerase chain reaction. LBD was evaluated using standard radiographs. Enzyme‐linked immunosorbent assay (ELISA) was performed on matched bone marrow plasma and immunohistochemistry on matched formalin‐fixed paraffin‐embedded biopsies. Gene expression of HGF, SDC1, and MET in BMBs were significantly altered in MM versus HV and MGUS, and HGF and MET correlated with the extent of LBD. A significant correlation between gene and protein expression levels was observed for SDC1 (Syndecan‐1) and HGF. The HGF bone marrow plasma level was significantly lower in MM patients with no/limited versus advanced LBD. Our novel approach using snap‐frozen BMBs seems generally applicable because it allows evaluation of gene expression independent of the extent of MM plasma‐cell infiltration. Our study highlights the importance of the HGF pathway in MM LBD.